ARS Pharmaceuticals, Inc. (SPRY)

Market Cap	821.71M
Revenue (ttm)	30,000
Net Income (ttm)	-54.37M
Shares Out	96.50M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	362,662
Open	8.44
Previous Close	8.21
Day's Range	8.31 - 8.83
52-Week Range	2.55 - 11.27
Beta	n/a
Analysts	Buy
Price Target	18.50 (+117.26%)
Earnings Date	May 13, 2024

About SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRY

Financial Performance

In 2023, SPRY's revenue was $30,000, a decrease of -97.72% compared to the previous year's $1.32 million. Losses were -$54.37 million, 56.8% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 117.26% from the latest price.

Price Target

$18.5

(117.26% upside)

Analyst Consensus: Buy